1
|
Jalilian A, Decristoforo C, Denecke M, Elsinga PH, Hoehr C, Korde A, Lapi SE, Scott PJH. Proceedings of international symposium of trends in radiopharmaceuticals 2023 (ISTR-2023). EJNMMI Radiopharm Chem 2023; 8:39. [PMID: 37950112 PMCID: PMC10638263 DOI: 10.1186/s41181-023-00224-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/05/2023] [Accepted: 10/29/2023] [Indexed: 11/12/2023] Open
Abstract
The International Atomic Energy Agency (IAEA) held the 3rd International Symposium on Trends in Radiopharmaceuticals, (ISTR-2023) at IAEA Headquarters in Vienna, Austria, during the week of 16-21 April 2023. This procedural paper summarizes highlights from symposium presentations, posters, panel discussions and satellite meetings, and provides additional resources that may be useful to researchers working with diagnostic and therapeutic radiopharmaceuticals in the academic, government and industry setting amongst IAEA Member States and beyond. More than 550 participants in person from 88 Member States attended the ISTR-2023. Over 360 abstracts were presented from all over the world by a diverse group of global scientists working with radiopharmaceuticals. Given this group of international radiochemists is unique to ISTR (IAEA funding enabled many to attend), there was an invaluable wealth of knowledge on the global state of the radiopharmaceutical sciences present at the meeting. The intent of this Proceedings paper is to share this snapshot from our international colleagues with the broader radiopharmaceutical sciences community by highlighting presentations from the conference on the following topics: Isotope Production and Radiochemistry, Industrial Insights, Regional Trends, Training and Education, Women in the Radiopharmaceutical Sciences, and Future Perspectives and New Initiatives. The authors of this paper are employees of IAEA, members of the ISTR-2023 Organizing Committee and/or members of the EJNMMI Radiopharmacy and Chemistry Editorial Board who attended ISTR-2023. Overall, ISTR-2023 fostered the successful exchange of scientific ideas around every aspect of the radiopharmaceutical sciences. It was well attended by a diverse mix of radiopharmaceutical scientists from all over the world, and the oral and poster presentations provided a valuable update on the current state-of-the-art of the field amongst IAEA Member States. Presentations as well as networking amongst the attendees resulted in extensive knowledge transfer amongst the various stakeholders representing 88 IAEA Member States. This was considered particularly valuable for attendees from Member States where nuclear medicine and the radiopharmaceutical sciences are still relatively new. Since the goal is for the symposium series to be held every four years; the next one is anticipated to take place in 2027.
Collapse
Affiliation(s)
- Amirreza Jalilian
- Division of Physical and Chemical Sciences, International Atomic Energy Agency, Vienna, Austria
| | - Clemens Decristoforo
- Department of Nuclear Medicine, Medical University Innsbruck, Innsbruck, Austria
| | - Melissa Denecke
- Division of Physical and Chemical Sciences, International Atomic Energy Agency, Vienna, Austria
| | - Philip H Elsinga
- Department of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, Groningen, The Netherlands
| | | | - Aruna Korde
- Division of Physical and Chemical Sciences, International Atomic Energy Agency, Vienna, Austria
| | - Suzanne E Lapi
- Departments of Radiology and Chemistry, O'Neal Comprehensive Cancer Center at UAB, University of Alabama at Birmingham, Birmingham, AL, USA
| | - Peter J H Scott
- Department of Radiology, University of Michigan, Ann Arbor, MI, USA.
| |
Collapse
|
2
|
Alberto S, Ordonez AA, Arjun C, Aulakh GK, Beziere N, Dadachova E, Ebenhan T, Granados U, Korde A, Jalilian A, Lestari W, Mukherjee A, Petrik M, Sakr T, Cuevas CLS, Welling MM, Zeevaart JR, Jain SK, Wilson DM. The Development and Validation of Radiopharmaceuticals Targeting Bacterial Infection. J Nucl Med 2023; 64:1676-1682. [PMID: 37770110 PMCID: PMC10626374 DOI: 10.2967/jnumed.123.265906] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/27/2023] [Revised: 08/18/2023] [Indexed: 10/03/2023] Open
Abstract
The International Atomic Energy Agency organized a technical meeting at its headquarters in Vienna, Austria, in 2022 that included 17 experts representing 12 countries, whose research spanned the development and use of radiolabeled agents for imaging infection. The meeting focused largely on bacterial pathogens. The group discussed and evaluated the advantages and disadvantages of several radiopharmaceuticals, as well as the science driving various imaging approaches. The main objective was to understand why few infection-targeted radiotracers are used in clinical practice despite the urgent need to better characterize bacterial infections. This article summarizes the resulting consensus, at least among the included scientists and countries, on the current status of radiopharmaceutical development for infection imaging. Also included are opinions and recommendations regarding current research standards in this area. This and future International Atomic Energy Agency-sponsored collaborations will advance the goal of providing the medical community with innovative, practical tools for the specific image-based diagnosis of infection.
Collapse
Affiliation(s)
- Signore Alberto
- Nuclear Medicine Unit, Department of Medical-Surgical Sciences and Translational Medicine, Faculty of Medicine and Psychology, University of Rome "Sapienza," Rome, Italy
| | - Alvaro A Ordonez
- Center for Infection and Inflammation Imaging Research, Johns Hopkins University School of Medicine, Baltimore, Maryland
| | - Chanda Arjun
- Radiopharmaceutical Program, Board of Radiation and Isotope Technology, Mumbai, India
| | - Gurpreet Kaur Aulakh
- Department of Small Animal Clinical Sciences, Western College of Veterinary Medicine, University of Saskatchewan, Saskatoon, Saskatchewan, Canada
| | - Nicolas Beziere
- Werner Siemens Imaging Center, Department of Preclinical Imaging and Radiopharmacy, Eberhard Karls University of Tübingen, Tübingen, Germany
| | - Ekaterina Dadachova
- College of Pharmacy and Nutrition, University of Saskatchewan, Saskatoon, Saskatchewan, Canada
| | - Thomas Ebenhan
- Nuclear Medicine, University of Pretoria, and Radiochemistry, Applied Radiation, South African Nuclear Energy Corporation, Pelindaba, South Africa
| | - Ulises Granados
- Department of Nuclear Medicine, Hospital Internacional de Colombia-Fundación Cardiovascular de Colombia, Piedecuesta, Colombia
| | - Aruna Korde
- Department of Nuclear Sciences and Applications, International Atomic Energy Agency, Vienna, Austria
| | - Amirreza Jalilian
- Department of Nuclear Sciences and Applications, International Atomic Energy Agency, Vienna, Austria
| | - Wening Lestari
- National Nuclear Energy Agency, South Tangerang, Indonesia
| | - Archana Mukherjee
- Radiopharmaceuticals Division, Bhabha Atomic Research Centre, Mumbai, India
| | - Milos Petrik
- Institute of Molecular and Translational Medicine and Czech Advanced Technology and Research Institute, Faculty of Medicine and Dentistry, Palacky University Olomouc, Olomouc, Czech Republic
| | - Tamer Sakr
- Radioactive Isotopes and Generator Department, Hot Labs Center, Egyptian Atomic Energy Authority, Cairo, Egypt
| | | | - Mick M Welling
- Interventional Molecular Imaging Laboratory, Department of Radiology, Leiden University Medical Center, Leiden, The Netherlands; and
| | - Jan Rijn Zeevaart
- Nuclear Medicine, University of Pretoria, and Radiochemistry, Applied Radiation, South African Nuclear Energy Corporation, Pelindaba, South Africa
| | - Sanjay K Jain
- Center for Infection and Inflammation Imaging Research, Johns Hopkins University School of Medicine, Baltimore, Maryland
| | - David M Wilson
- Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, California
| |
Collapse
|
3
|
Radchenko V, Morgenstern A, Jalilian A, Ramogida C, Cutler CS, Duchemin C, Hoehr C, Haddad F, Bruchertseifer F, Gausemel H, Yang H, Osso JA, Washiyama K, Czerwinski K, Leufgen K, Pruszynski M, Valzdorf O, Causey P, Schaffer P, Perron R, Samsonov M, Wilbur DS, Stora T, Li Y. Production and supply of alpha particles emitting radionuclides for Targeted Alpha Therapy (TAT). J Nucl Med 2021; 62:1495-1503. [PMID: 34301779 DOI: 10.2967/jnumed.120.261016] [Citation(s) in RCA: 40] [Impact Index Per Article: 13.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/05/2021] [Accepted: 06/29/2021] [Indexed: 11/16/2022] Open
Abstract
Encouraging results of Targeted Alpha Therapy (TAT) have created significant attention from academia and industry. However, the limited availability of suitable radionuclides has hampered widespread translation and application. In the present review, we discuss the most promising candidates for clinical application and the state of the art of their production and supply. Along with forthcoming another two reviews on chelation and clinical application of alpha-emitting radionuclides, JNM will provide a comprehensive assessment of the field.
Collapse
|
4
|
Jalilian A, Alberto Osso J, Korde A, Valeriia S. The role of IAEA in the Development of Radiopharmaceutical Sciences with Focus on Alpha Emitters. J Med Imaging Radiat Sci 2019. [DOI: 10.1016/j.jmir.2019.11.057] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
5
|
Giammarile F, Castellucci P, Dierckx R, Estrada Lobato E, Farsad M, Hustinx R, Jalilian A, Pellet O, Rossi S, Paez D. Non-FDG PET/CT in Diagnostic Oncology: a pictorial review. Eur J Hybrid Imaging 2019; 3:20. [PMID: 34191163 PMCID: PMC8218094 DOI: 10.1186/s41824-019-0066-2] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/08/2019] [Accepted: 10/22/2019] [Indexed: 11/25/2022] Open
Abstract
Positron emission tomography/computed tomography (PET/CT) is currently one of the main imaging modalities for cancer patients worldwide. Fluorodeoxyglucose (FDG) PET/CT has earned its global recognition in the modern management of cancer patients and is rapidly becoming an important imaging modality for patients with cardiac, neurological, and infectious/inflammatory conditions. Despite its proven benefits, FDG has limitations in the assessment of several relevant tumours such as prostate cancer. Therefore, there has been a pressing need for the development and clinical application of different PET radiopharmaceuticals that could image these tumours more precisely. Accordingly, several non-FDG PET radiopharmaceuticals have been introduced into the clinical arena for management of cancer. This trend will undoubtedly continue to spread internationally. The use of PET/CT with different PET radiopharmaceuticals specific to tumour type and biological process being assessed is part of the personalised precision medicine approach. The objective of this publication is to provide a case-based method of understanding normal biodistribution, variants, and pitfalls, including several examples of different imaging appearances for the main oncological indications for each of the new non-FDG PET radiopharmaceuticals. This should facilitate the interpretation and recognition of common variants and pitfalls to ensure that, in clinical practice, the official report is accurate and helpful. Some of these radiopharmaceuticals are already commercially available in many countries (e.g. 68Ga-DOTATATE and DOTATOC), others are in the process of becoming available (e.g. 68Ga-PSMA), and some are still being researched. However, this list is subject to change as some radiopharmaceuticals are increasingly utilised, while others gradually decrease in use.
Collapse
Affiliation(s)
- Francesco Giammarile
- Department of Nuclear Sciences and Applications, International Atomic Energy Agency, Vienna, Austria.
| | - Paolo Castellucci
- Department of Nuclear Medicine, Sant'Orsola-Malpighi Hospital, 40138, Bologna, Italy
| | - Rudi Dierckx
- Medical Imaging Center, Department of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, Groningen, The Netherlands
| | - Enrique Estrada Lobato
- Department of Nuclear Sciences and Applications, International Atomic Energy Agency, Vienna, Austria
| | - Mohsen Farsad
- Department of Nuclear Medicine, Bolzano Hospital, Bolzano, Italy
| | - Roland Hustinx
- Department of Nuclear Medicine, CHU Liège, University of Liège, Liège, Belgium
| | - Amirreza Jalilian
- Department of Nuclear Sciences and Applications, International Atomic Energy Agency, Vienna, Austria
| | - Olivier Pellet
- Department of Nuclear Sciences and Applications, International Atomic Energy Agency, Vienna, Austria
| | - Susana Rossi
- Centro Uruguayo de Imagenología Molecular (CUDIM), Montevideo, Uruguay
| | - Diana Paez
- Department of Nuclear Sciences and Applications, International Atomic Energy Agency, Vienna, Austria
| |
Collapse
|
6
|
Farahati J, Kazek S, Maric I, Soestwoehner T, Kalle P, Costa PF, Jentzen W, Stein L, Jalilian A, Kumm D, Bockisch A, Herrmann K. Post-radiosynovectomy imaging utilizing Erbium-169 citrate. Appl Radiat Isot 2019; 154:108853. [PMID: 31493660 DOI: 10.1016/j.apradiso.2019.108853] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/25/2019] [Revised: 07/26/2019] [Accepted: 08/11/2019] [Indexed: 11/16/2022]
Abstract
Currently, there is no imaging procedure for radionuclide therapy utilizing Erbium-169 (Er-169). We have recently published the first post-radiosynovectomy imaging of Er-169 citrate in a case report (Farahati et al., 2017). In this study, we performed in-vitro and in-vivo studies to evaluate the feasibility to assess the distribution of Er-169 citrate after radiosynovectomy in fourteen patients with seventeen affected joints treated for refractory chronic synovitis. Post-radiosynovectomy imaging revealed the feasibility of post-radiosynovectomy detection and distribution utilizing Er-169 citrate in all cases. However, additional in-vitro studies including in-vitro imaging, gamma spectrometry and analysis of half-life indicated that emitted gamma-rays of the Ytterbium-169 in the radiopharmaceutical together with bremsstrahlung induced by Er-169 are the imaging source of emitted counts. Post-radiosynovectomy imaging utilizing Er-169 citrate is feasible and should be implemented in the guidelines for theranostics for quality control, patient safety and therapy monitoring.
Collapse
Affiliation(s)
- Jamshid Farahati
- Clinic for Nuclear Medicine, Bethesda, Duisburg, Germany; Clinic for Nuclear Medicine, University Hospital Essen, Germany.
| | - Sandra Kazek
- Clinic for Nuclear Medicine, Bethesda, Duisburg, Germany
| | - Ines Maric
- Clinic for Nuclear Medicine, Bethesda, Duisburg, Germany
| | | | - Patrick Kalle
- Clinic for Nuclear Medicine, University Hospital Essen, Germany
| | | | - Walter Jentzen
- Clinic for Nuclear Medicine, University Hospital Essen, Germany
| | - Linda Stein
- Clinic for Nuclear Medicine, Bethesda, Duisburg, Germany
| | - Amirreza Jalilian
- Department of Nuclear Sciences and Applications, International Atomic Energy Agency (IAEA), Vienna, Austria
| | - Dietmar Kumm
- Clinic for Orthopaedic, Bethesda, Duisburg, Germany
| | | | - Ken Herrmann
- Clinic for Nuclear Medicine, University Hospital Essen, Germany
| |
Collapse
|
7
|
Aguilar-Ortiz E, Jalilian A, Ávila-Rodríguez M. Synthesis, characterization and labeling of [64Cu]-5-(4-aminophenyl)-10,15,20-triphenyl porphyrine as a potential PET imaging chelate. Nucl Med Biol 2019. [DOI: 10.1016/s0969-8051(19)30289-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
8
|
Jalilian A, Alberto Osso J, Korde A, Valeriia S. The role of IAEA in the Development of Radiopharmaceutical Sciences with Focus on Alpha Emitters. J Med Imaging Radiat Sci 2019. [DOI: 10.1016/j.jmir.2019.03.052] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
9
|
Fazaeli Y, Shanehsazzadeh S, Lahooti A, Feizi S, Jalilian A. Preclinical dosimetric estimation of [111In] 5, 10, 15, 20-tetra phenyl porphyrin complex as a possible imaging/PDT agent. RADIOCHIM ACTA 2016. [DOI: 10.1515/ract-2015-2444] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
Abstract
Introduction: Recent studies show that porphyrin derivatives have interesting pharmacological and photodynamic properties and
wide range of usage in photodynamic therapy treatment. This study describes the preparation, biodistribution and absorbed dose
prediction of [111In] labeled 5, 10, 15, 20-tetra phenyl porphyrin (TPP) in human organs, based on rats' biodistribution
data. Methods: Five rats were sacrificed at each exact time intervals (2, 4 and 24 h post injection) and the
percentage of injected dose per gram of each organ was measured by direct counting from rats data from 12 harvested organs. The Medical
Internal Radiation Dose (MIRD) formulation was applied to extrapolate from rats to human and to project the absorbed radiation dose for
various organs in humans. Results: From rat data we estimated that injection of [111In] TPP into the humans would
result in an estimated effective absorbed dose of 0.09 mSv/MBq in the whole body. While the highest effective absorbed dose
for 111In-TPP was in the heart wall (0.22 mSv), the organs that received the next highest doses were the Kidneys
(0.06 mSv), thymus (0.04 mSv) and lungs (0.03 mSv). Conclusions: The skin dose will four
times higher compare to the other 111In compounds, which was due to magnificent skin uptakes. According to the fast
wash-out, tumor avidity and the short half-life, [111In] can be a suitable candidate for labeling of photo dynamic therapy
(PDT) agents as a tracer for accurate biological evaluation of other PDT agents such as Photofrin and its homologs.
Collapse
Affiliation(s)
- Yousef Fazaeli
- Nuclear Science and Technology Research Institute (NSTRI), Box 14395-836, Tehran, Iran
| | - Saeed Shanehsazzadeh
- Nuclear Science and Technology Research Institute (NSTRI), Box 14395-836, Tehran, Iran
| | - Afsaneh Lahooti
- Department of Medical Physics and Biomedical Engineering, Faculty of Medicine, Tehran University of Medical Sciences, Tehran, Iran
| | - Shahzad Feizi
- Nuclear Science and Technology Research Institute (NSTRI), Box 14395-836, Tehran, Iran
| | - Amirreza Jalilian
- Nuclear Science and Technology Research Institute (NSTRI), Box 14395-836, Tehran, Iran
| |
Collapse
|
10
|
Fazaeli Y, Amini MM, Najafi E, Mohajerani E, Janghouri M, Jalilian A, Ng SW. Synthesis and Characterization of 8-hydroxyquinoline Complexes of Tin(IV) and Their Application in Organic Light Emitting Diode. J Fluoresc 2012; 22:1263-70. [DOI: 10.1007/s10895-012-1068-7] [Citation(s) in RCA: 31] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/19/2012] [Accepted: 05/28/2012] [Indexed: 10/28/2022]
|
11
|
Behrooz A, Rasaee M, Jalilian A, Rajabifar S, Kamal Y, Javad M, Afsaneh B, Mojtaba F. Synthesis and biodistribution studies of 67Ga-DOTA-trastuzumab as a diagnostic radioimmunoconjugate for oncology imaging by SPECT. Clin Biochem 2011. [DOI: 10.1016/j.clinbiochem.2011.08.1022] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
12
|
Moghaddam L, Jalilian A. SU-E-T-325: Development of a Radioscandium Immunoconjugate for Radioimunotherapy. Med Phys 2011. [DOI: 10.1118/1.3612279] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|